이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

활동성 건선성 관절염 축 질환이 있는 생체 순진한 참가자에서 피하 투여된 Guselkumab에 대한 연구 (STAR)

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

A 4상, 다기관, 무작위, 이중 맹검, 위약 대조 연구 활동성 건선성 관절염 축 질환이 있는 생체 순진한 참여자에서 피하로 투여된 Guselkumab의 효능 및 안전성 평가

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and inflammation.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

PsA is a chronic inflammatory musculoskeletal disease that has 6 disease domains, and axial disease represents one of the domains. Guselkumab is a fully human immunoglobulin (Ig) G1 lambda monoclonal antibody (mAb) that by binding to the p19 protein subunit of interleukin (IL)-23, blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23-mediated intracellular signaling, activation, and cytokine production. This study will consist of a screening phase (up to 6 weeks), a treatment phase (up to 48 weeks, including a placebo-controlled period from Week 0 to Week 24 and an active-controlled treatment phase from Week 24 to Week 48), and a safety follow-up phase (up to Week 60). The efficacy assessments will include assessment such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score and the safety assessments will include evaluations of physical examinations, vital signs, electrocardiograms, clinical laboratory tests, and adverse events. The overall duration of the study will be up to 14 months.

연구 유형

중재적

등록 (실제)

411

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Batumi, 그루지야, 6010
        • Ltd Health Center
      • Kutaisi, 그루지야, 4600
        • LTD Clinic LJ
      • Tbilisi, 그루지야, 0112
        • LTD Helsicore
      • Tbilisi, 그루지야, 0102
        • Aleksandre Aladashvili Clinic LLC
      • Tbilisi, 그루지야, 0141
        • TSMU The First University Clinic
      • Tbilisi, 그루지야, 0179
        • Clinic on Mtskheta Street
      • Tbilisi, 그루지야, 0186
        • Consilium Medulla-multiprofile clinic Ltd
      • Tbilisi, 그루지야, 0160
        • LTD MediClub Georgia
      • Tbilisi, 그루지야, 0180
        • LTD The First Medical Center
      • Tbilisi, 그루지야, 0160
        • LTD 'Aversi Clinic'
      • Tbilisi, 그루지야, 0102
        • Ltd American Hospital Network
      • Tbilisi, 그루지야, 0159
        • JSC K Eristavi National Center of experimental and Clinical surgery
      • Tbilisi, 그루지야, 0159
        • Tbilisi Heart and Vascular Clinic Ltd
      • Tbilisi, 그루지야, 0114
        • Ltd New Hospitals
      • Tnilisi, 그루지야, 0159
        • JSC Evex Hospitals
      • Hsinchu, 대만, 30059
        • National Taiwan University Hospital
      • Tainan, 대만, 704
        • National Cheng Kung University Hospital
      • Taoyuan, 대만, 33305
        • Linkou Chang Gung Memorial Hospital
      • Frederiksberg, 덴마크, 2000
        • Frederiksberg Hospital
      • Glostrup Municipality, 덴마크, 2600
        • Rigshospitalet Glostrup
      • Køge, 덴마크, 4600
        • Køge Sygehus Region Sjaelland
      • Vejle, 덴마크, 7100
        • Vejle Sygehus
      • Berlin, 독일, 10789
        • ISA - Interdisciplinary Study Association GmbH
      • Hamburg, 독일, 20095
        • Hamburger Rheuma Forschungszentrum II
      • Herne, 독일, 44649
        • Rheumazentrum Ruhrgebiet
      • Ratingen, 독일, 40878
        • Rheumazentrum Ratingen
      • Barnaul, 러시아 제국, 656038
        • Altay Medical State University
      • Chelyabinsk, 러시아 제국, 454076
        • Chelyabinck Regional Clinical Hospital
      • Chelyabinsk, 러시아 제국, 454092
        • Chelyabinsk Regional Clinical Dermatovenerological Dispensary
      • Izhevsk, 러시아 제국, 426009
        • Regional Clinical Diagnostic Center of Udmurtia Region
      • Kemerovo, 러시아 제국, 650070
        • LLL Medical Center Revma-Med
      • Korolyov, 러시아 제국, 141060
        • LLC Family Outpatient Clinic # 4
      • Krasnoyarsk, 러시아 제국, 660123
        • Regional SBI of PH Krasnoyarsk Regional Clinical hospital #20 named after I.S. Berzon
      • Moscow, 러시아 제국, 115419
        • Clinical-Diagnostic Center Euromedservice, JSC
      • Moscow, 러시아 제국, 115522
        • FGBU Research Institute of Rheumatology named V.A.Nasonova
      • Moscow, 러시아 제국, 129110
        • GBUZ of Moscow Region 'Moscow Region SRI n.a. Vladimirskyi'
      • Omsk, 러시아 제국, 644024
        • Llc Ultramed
      • Orenburg, 러시아 제국, 460000
        • GBOU VPO Orenburg State Medical University
      • Perm, 러시아 제국, 614990
        • GBUZ Perm Regional Clinical Hospital
      • Petrozavodsk, 러시아 제국, 185019
        • Republican Hospital n.a.V.A.Baranov
      • Rostov-on-Don, 러시아 제국, 344007
        • Rostov Regional Clinical Dermatovenerological Dispensary
      • Saint Petersburg, 러시아 제국, 190068
        • St. Petersburg GBUZ Clinical Reumatological Hospital 25
      • Saint Petersburg, 러시아 제국, 194156
        • X7 Clinical Research Company Limited
      • Tolyatti, 러시아 제국, 445846
        • GBUZ of Samara Region 'Tolyatti City Clinical Hospital 5'
      • Ufa, 러시아 제국, 450005
        • Republican Clinical Hospital - G.G. Kuvatov
      • Yaroslavl, 러시아 제국, 150007
        • Clinical Hospital #3
      • Yekaterinburg, 러시아 제국, 620102
        • Sverdlovsk Regional Clinical Hospital N. 1
      • Batu Caves, 말레이시아, 68100
        • Hospital Selayang
      • George Town, 말레이시아, 10990
        • Hospital Pulau Pinang
      • Johor Bahru, 말레이시아, 81100
        • Hospital Sultan Ismail
      • Kuala Lumpur, 말레이시아, 59100
        • University Malaya Medical Centre
      • Seremban, 말레이시아, 70300
        • Hospital Tuanku Jaafar
    • Arizona
      • Avondale, Arizona, 미국, 85392
        • Arizona Arthritis and Rheumatology Research PLLC 1
      • Chandler, Arizona, 미국, 85225
        • Arizona Arthritis & Rheumatology Research, PLLC
      • Mesa, Arizona, 미국, 85210
        • Arizona Arthritis and Rheumatology Research PLLC
      • Phoenix, Arizona, 미국, 85032
        • Arizona Arthritis Research, PLC.
      • Sun City, Arizona, 미국, 85351
        • Arizona Arthritis and Rheumatology Associates
      • Tucson, Arizona, 미국, 85723
        • Southern Arizona VA Healthcare System
    • Arkansas
      • Searcy, Arkansas, 미국, 72143
        • Unity Health-White County Medical Center
    • California
      • Fontana, California, 미국, 92335
        • Kaiser Permanent Medical Center
      • Huntington Beach, California, 미국, 92648
        • Newport Huntington Medical Group
      • La Jolla, California, 미국, 92093
        • University Of California San Diego
      • San Diego, California, 미국, 92128
        • Rheumatology Center of San Diego
    • Connecticut
      • Danbury, Connecticut, 미국, 06810
        • Clinical Research Center of Connecticut
    • Florida
      • Bay Pines, Florida, 미국, 33744
        • Bay Pines VA Healthcare System
      • Plantation, Florida, 미국, 33324
        • Integral Rheumatology And Immunology Specialists
      • Zephyrhills, Florida, 미국, 33542
        • Florida Medical Clinic, P.A.
    • Illinois
      • Chicago, Illinois, 미국, 60640
        • Great Lakes Clinical Trials
      • Rockford, Illinois, 미국, 61114
        • OrthoIllinois
      • Willowbrook, Illinois, 미국, 60527
        • Willow Rheumatology and Wellness
    • Maryland
      • Baltimore, Maryland, 미국, 21224
        • Johns Hopkins Bayview Medical
      • Hagerstown, Maryland, 미국, 21740
        • Klein And Associates M D P A
    • Michigan
      • Saint Clair Shores, Michigan, 미국, 48081
        • Clinical Research Institute of Michigan, LLC
    • Minnesota
      • Eagan, Minnesota, 미국, 55121
        • St. Paul Rheumatology P A
    • Missouri
      • Kansas City, Missouri, 미국, 64111
        • Kansas City Physician Partners
      • Springfield, Missouri, 미국, 65807
        • Clinvest
    • Ohio
      • Vandalia, Ohio, 미국, 45377
        • STAT Research, Inc.
    • Oregon
      • Portland, Oregon, 미국, 97239
        • OHSU Rheumatology Clinic, Marquam Hill
    • Texas
      • Amarillo, Texas, 미국, 79124
        • Amarillo Center for Clinical Research
      • Austin, Texas, 미국, 78731
        • Austin Regional Clinic
      • Colleyville, Texas, 미국, 76034
        • Precision Comprehensive Clinical Research Solutions
      • Corpus Christi, Texas, 미국, 78404
        • Adriana Pop Moody MD Clinic PA
      • Fort Worth, Texas, 미국, 76109
        • AARA Clinical Research Lone Star Arthritis and Rheumatology 1
      • Houston, Texas, 미국, 77030
        • UT Physicians Center for Autoimmunity
      • Irving, Texas, 미국, 75039
        • AARA Clinical Research Lone Star Arthritis and Rheumatology
      • Lubbock, Texas, 미국, 79424
        • West Texas Clinical Research
      • Mesquite, Texas, 미국, 75150
        • Southwest Rheumatology Research LLC
      • Red Oak, Texas, 미국, 75154
        • Epic Medical Research
      • Tomball, Texas, 미국, 77375
        • DM Clinical Research
    • Washington
      • Seattle, Washington, 미국, 98104
        • Swedish Medical Center
      • Pleven, 불가리아, 5804
        • UMHAT 'Dr. Georgi Stranski', EAD
      • Pleven, 불가리아, 5803
        • Exacta Medica
      • Plovdiv, 불가리아, 4001
        • UMHAT Kaspela
      • Plovdiv, 불가리아, 4001
        • Medical Center Unimed Plovdiv
      • Plovdiv, 불가리아, 4002
        • Medical Center Artmed
      • Sofia, 불가리아, 1606
        • Military Medical Academy
      • Sofia, 불가리아, 1680
        • DCC Convex EOOD
      • Sofia, 불가리아, 1794
        • Medical Centre Synexus
      • Sofia, 불가리아, 1336
        • MHAT 'Lyulin' EAD
      • Sofia, 불가리아, 1612
        • UMHAT St. Ivan Rilski
      • Sofia, 불가리아, 1750
        • ASIMP Rheumatology Centre St Irina EOOD
      • Sofia, 불가리아, 1336
        • University Multiprofile Hospital Sofiamed Sofia
      • Targovishte, 불가리아, 7700
        • DDC Sv. Ivan Rilski OOD
      • Solna, 스웨덴, 171 76
        • Karolinska Universitetssjukhuset
      • Uppsala, 스웨덴, 753 09
        • Akademiska Sjukhuset
      • A Coruña, 스페인, 15006
        • Hosp Univ A Coruna
      • Barakaldo, 스페인, 48902
        • Hosp. Univ. de Cruces
      • Barcelona, 스페인, 08036
        • Hosp Clinic de Barcelona
      • Bilbao, 스페인, 48013
        • Hosp. Univ. de Basurto
      • Córdoba, 스페인, 14004
        • Hosp Reina Sofia
      • Madrid, 스페인, 28040
        • Hosp. Clinico San Carlos
      • Málaga, 스페인, 29009
        • Hosp Regional Univ de Malaga
      • Sabadell, 스페인, 8208
        • Corporacio Sanitari Parc Tauli
      • Santiago de Compostela, 스페인, 15702
        • Clinica Gaias
      • Seville, 스페인, 41009
        • Hosp. Virgen Macarena
      • Seville, 스페인, 41013
        • Hosp. Quiron Sagrado Corazon
      • Valencia, 스페인, 46026
        • Hosp. Univ. I Politecni La Fe
      • Martin, 슬로바키아, 036 01
        • Reumatologicka Ambulancia 1
      • Nové Mesto nad Váhom, 슬로바키아, 91501
        • Reumatologicka ambulancia
      • Piešťany, 슬로바키아, 921 01
        • Reumatologická ambulancia Thermium s.r.o.
      • Poprad, 슬로바키아, 05801
        • REUMAMED POPRAD, s.r.o.
      • Rimavská Sobota, 슬로바키아
        • Reumex s.r.o
      • Buenos Aires, 아르헨티나, C1199ABB
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, 아르헨티나, C1417
        • Centro Privado de Medicina Familiar
      • Buenos Aires, 아르헨티나, 1428
        • Cosultorios Reumatologógicos Pampa
      • La Plata, 아르헨티나, B1900
        • Hospital Italiano La Plata
      • San Fernando, 아르헨티나, B1646
        • MR Medicina Reumatologica
      • San Miguel de Tucumán, 아르헨티나, T4000AXL
        • Centro Medico Privado de Reumatologia
      • Barnet, 영국, EN5 3DJ
        • Royal Free London NHS Foundation Trust
      • Bradford, 영국, BD5 0NA
        • St. Lukes Hospital
      • Coventry, 영국, CV2 2DX
        • University Hospital Coventry & Warwickshire NHS Trust
      • Leeds, 영국, LS7 4SA
        • Chapel Allerton Hospital
      • Manchester, 영국, M13 9WL
        • Central Manchester University Hospitals NHS Foundation Trust
      • Newcastle, 영국, NE29 8NH
        • North Tyneside General Hospital
      • Stoke-on-Trent, 영국, ST6 7AG
        • Haywood Hospital
      • Cherkasy, 우크라이나, 18009
        • Communal Noncommercial Enterprise Cherkasy Regional Hospital of Cherkasy Regional Council
      • Kharkiv, 우크라이나, 61204
        • Municipal non-commercial enterprise of Kharkiv Regional Council Regional Clinical Hospital
      • Khmelnytsky, 우크라이나, 29000
        • Khmelnitckiy regional hospital
      • Kryvyi Rih, 우크라이나, 50056
        • City Clinical Hospital No. 2
      • Kyiv, 우크라이나, 03049
        • Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'
      • Kyiv, 우크라이나, 03680
        • SI National Scientific Center Institute of Cardiology of M.D. Strazhesko of NAMS of Ukraine
      • Kyiv, 우크라이나, 02081
        • Medical Center of 'Institute of Rheumatology', LLC
      • Lutsk, 우크라이나, 43005
        • Volyn Regional Clinical Hospital
      • Odesa, 우크라이나, 65025
        • Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council
      • Poltava, 우크라이나, 36011
        • ME Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil
      • Ternopil, 우크라이나, 46002
        • Municipal institution of Tepnopil Regional Council 'Ternopil University Hospital'
      • Vinnytsia, 우크라이나, 21009
        • Health Clinic Limited Liability Company
      • Zaporizhzhya, 우크라이나, 69600
        • Medical Center LLC 'Modern Clinic'
      • Haifa, 이스라엘, 31048
        • Bnai Zion Medical Center
      • Haifa, 이스라엘, 34362
        • Carmel Medical Center
      • Holon, 이스라엘, 5822012
        • Wolfson Medical Center
      • Kfar Saba, 이스라엘, 4428164
        • Meir Medical Center
      • Ramat Gan, 이스라엘, 5265601
        • Sheba Medical Center
      • Ancona, 이탈리아, 60126
        • A.O. Universitaria Ospedali Riuniti di Ancona
      • Monserrato, 이탈리아, 09124
        • Azienda Ospedaliero-Universitaria di Cagliari
      • Reggio Emilia, 이탈리아, 42123
        • Arcispedale Santa Maria Nuova - IRCCS
      • Roma, 이탈리아, 00133
        • Policlinico Tor Vergata
      • Rozzano (MI), 이탈리아, 20089
        • Humanitas Hospital
      • Verona, 이탈리아, 37126
        • Azienda Ospedaliera Universitaria Integrata Verona
      • Brno, 체코, 61141
        • Revmaclinic
      • Brno, 체코, 63800
        • Revmatologie s r o
      • Brno-Židenice, 체코, 615 00
        • Revmacentrum MUDr Mostera s r o
      • Hlučín, 체코, 748 01
        • L K N Arthrocentrum
      • Karvina Frystat, 체코, 73301
        • Revimex Pro s r o
      • Ostrava, 체코, 70800
        • MUDr Rosypalova s r o
      • Pardubice, 체코, 53002
        • Arthrohelp S.R.O.
      • Prague, 체코, 128 00
        • Revmatologicky ustav
      • Uherské Hradiště, 체코, 68601
        • Medical Plus S R O
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 4E8
        • Skin Care Centre
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, 캐나다, A1C 5B8
        • Eastern Regional Health Authority St Clares Mercy Hospital
    • Ontario
      • Toronto, Ontario, 캐나다, M5T 2S8
        • Toronto Western Hospital
    • Quebec
      • Québec, Quebec, 캐나다, G1V 3M7
        • G R M O Groupe de recherche en maladies osseuses Inc
      • Bangkok, 태국, 10400
        • Phramongkutklao Hospital and Medical College
      • Bangkok, 태국, 10400
        • Ramathibodi Hospital Mahidol University
      • Chiang Mai, 태국, 50200
        • Chiang Mai University
      • Adana, 터키 (Türkiye), 01370
        • Adana City Hospital
      • Ankara, 터키 (Türkiye), 06800
        • Ankara Bilkent City Hospital
      • Ankara, 터키 (Türkiye), 6100
        • Hacettepe University Medical Faculty
      • Ankara, 터키 (Türkiye), 06010
        • Gulhane Training and Research Hospital
      • Antalya, 터키 (Türkiye), 7059
        • Akdeniz University Medical Faculty
      • Bursa, 터키 (Türkiye), 16059
        • Uludag University Medical Faculty
      • Istanbul, 터키 (Türkiye), 34098
        • Istanbul University Cerrahpasa Medical Faculty
      • Istanbul, 터키 (Türkiye), 34899
        • Marmara University Medical Faculty
      • Konya, 터키 (Türkiye), 42080
        • Necmettin Erbakan University Meram Medical Faculty
      • Braga, 포르투갈, 4710-243
        • Uls Braga - Hosp. Braga
      • Guarda, 포르투갈, 6300-749
        • Ulsg - Hosp. Sousa Martins
      • Lisbon, 포르투갈, 1350-352
        • Hosp. Cuf Tejo
      • Lisbon, 포르투갈, 1649-035
        • Uls Santa Maria - Hosp. Santa Maria
      • Lisbon, 포르투갈, 1050 034
        • Ipr Inst Port de Reumatologia
      • Lisbon, 포르투갈, 1349-019
        • Uls Lisboa Ocidental - Hosp. Egas Moniz
      • Ponte de Lima, 포르투갈, 4990-041
        • Ulsam - Hosp. Conde de Bertiandos
      • Porto, 포르투갈, 4200 319
        • Uls Sao Joao - Hosp. Sao Joao
      • Bialystok, 폴란드, 15 879
        • ClinicMed Daniluk Nowak Spolka Komandytowa
      • Bydgoszcz, 폴란드, 85 168
        • Szpital Uniwersytecki nr 2 im dr Jana Biziela
      • Bytom, 폴란드, 41 902
        • Nzoz Bif Med
      • Elblag, 폴란드, 82-300
        • Centrum Kliniczno Badawcze
      • Elblag, 폴란드, 82-300
        • Ambulatorium sp. z o.o.
      • Krakow, 폴란드, 30-002
        • Malopolskie Badania Kliniczne Sp z o o
      • Krakow, 폴란드, 31-513
        • Centrum Medyczne Promed
      • Lodz, 폴란드, 90-338
        • Centrum Terapii Wspolczesnej J M Jasnorzewska Spolka Komandytowo Akcyjna
      • Lodz, 폴란드, 90-265
        • Dermed Centrum Medyczne Sp z o o
      • Lodz, 폴란드, 91 363
        • Centrum Medyczne AMED oddzial w Lodzi
      • Lublin, 폴란드, 20 607
        • Reumed Zespol Poradni Specjalistycznych Filia nr 1
      • Lublin, 폴란드, 20-412
        • Pro Life Medica Sp. z o.o.
      • Lublin, 폴란드, 20 831
        • Velocity Lublin
      • Nadarzyn, 폴란드, 05-830
        • NZOZ Lecznica MAK MED S C
      • Nowa Sól, 폴란드, 67-100
        • Twoja Przychodnia - Centrum Medyczne Nowa Sol
      • Poznan, 폴란드, 60 324
        • Twoja Przychodnia PCM
      • Poznan, 폴란드, 60-446
        • Reumedika s c Wieslawa Porawska Lukasz Porawski
      • Torun, 폴란드, 87-100
        • MICS Centrum Medyczne Torun
      • Warsaw, 폴란드, 02-793
        • ETG Warszawa
      • Warsaw, 폴란드, 00-874
        • MICS Centrum Medyczne Warszawa
      • Warsaw, 폴란드, 02 637
        • Narodowy Instytut Geriatrii Reumatologii i Rehabilitacji im prof dr hab med Eleonory Reicher
      • Warsaw, 폴란드, 02-665
        • Centrum Medyczne Reuma Park
      • Warsaw, 폴란드, 02 118
        • Rheuma Medicus Sp z o o
      • Warsaw, 폴란드, 03 291
        • Centrum Medyczne AMED Targowek
      • Wroclaw, 폴란드, 51 685
        • WroMedica I Bielicka A Strzalkowska s c
      • Świdnik, 폴란드, 21 040
        • Lubelskie Centrum Diagnostyczne
      • Cebu City, 필리핀 제도, 6000
        • Cebu Doctors' University Hospital
      • Davao City, 필리핀 제도, 8000
        • Davao Doctors Hospital
      • Lipa, 필리핀 제도, 4217
        • Lipa Medix Medical Hospital
      • Manila, 필리핀 제도, 1000
        • Philippine General Hospital
      • Manila, 필리핀 제도, 1000
        • ManilaMed Medical Center Manila
      • Quezon City, 필리핀 제도, 1112
        • St. Luke's Medical Center
      • San Fernando City, 필리핀 제도, 2500
        • Ilocos Training and Regional Medical Center
      • Budapest, 헝가리, 1036
        • Obudai Egeszsegugyi Centrum Kft
      • Budapest, 헝가리, 1023
        • Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
      • Budapest, 헝가리, H-1036
        • Qualiclinic Kft
      • Gyula, 헝가리, 5700
        • Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
      • Hódmezővásárhely, 헝가리, 6800
        • Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
      • Kistarcsa, 헝가리, 2143
        • Kistarcsai Flor Ferenc Korhaz
      • Székesfehérvár, 헝가리, 8000
        • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
      • Veszprém, 헝가리, 8200
        • Vital Medical Center Orvosi es Fogaszati Kozpont
      • Camberwell, 호주, 3124
        • Emeritus Research
      • Hobart, 호주, 7000
        • Southern Clinical Research
      • Liverpool, 호주, 2170
        • Liverpool Hospital
      • Maroochydore, 호주, 4558
        • Rheumatology Research Unit
      • Melbourne, 호주, 3128
        • Eastern Health - Box Hill Hospital
      • Melbourne, 호주, 3053
        • Skin Health Institute Inc.
      • Hong Kong, 홍콩
        • Prince Of Wales Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Have a diagnosis of psoriatic arthritis (PsA) for at least 6 months prior to the first administration of study intervention and meet classification criteria for psoriatic arthritis (CASPAR) criteria at screening
  • Have active PsA as defined by: a) at least 3 swollen joints and at least 3 tender joints at screening and at baseline and b) C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligram/deciliter (mg/dL) at screening from the central laboratory, and despite previous non-biologic disease modifying antirheumatic drug (DMARD), apremilast, and/or nonsteroidal anti-inflammatory drug (NSAID) therapy
  • Have magnetic resonance imaging (MRI)-confirmed PsA axial disease (positive MRI spine and/or sacroiliac [SI] joints, shown by a Spondyloarthritis Research Consortium of Canada [SPARCC] score of >= 3 in either the spine or the sacroiliac joints)
  • Have a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of at least 4, and have a spinal pain score (on a visual analog scale [VAS]) of at least 4
  • Have active plaque psoriasis, with at least 1 psoriatic plaque of >= 2 centimeter (cm) diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis

Exclusion Criteria:

  • Has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients
  • Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to rheumatoid arthritis (RA), ankylosing spondylitis (AS)/non-radiographic-axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, or Lyme disease
  • Has previously received any biologic treatment
  • Has ever received a Janus kinase (JAK) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other investigational JAK inhibitor
  • Has received any systemic immunosuppressants (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Group 1: Guselkumab and Placebo

Participants will receive guselkumab and matching placebo subcutaneously (SC) to maintain the blind.

Guselkumab will be administered as subcutaneous injection.

다른 이름들:
  • 트렘피아

Matching placebo will be administered as subcutaneous injection.

실험적: Group 2: Guselkumab

Participants will receive guselkumab SC.

Guselkumab will be administered as subcutaneous injection.

다른 이름들:
  • 트렘피아
실험적: Group 3: Placebo followed by Guselkumab

Participants will receive matching placebo and will cross over to receive guselkumab SC.

Guselkumab will be administered as subcutaneous injection.

다른 이름들:
  • 트렘피아

Matching placebo will be administered as subcutaneous injection.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change from Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 24
기간: Baseline and Week 24

BASDAI is a self-assessment tool that consists of 6 questions relating to 5 major symptoms of ankylosing spondylitis: fatigue, spinal pain, joint pain, enthesitis, qualitative morning stiffness and quantitative morning stiffness. First 5 items were scored on a 10 centimeter (cm) visual analog scale (VAS) ranging from 0 equals to (=) none to 10=very severe. Quantitative morning stiffness was scored on a 10 cm VAS ranging from 0=0 hours to 10=2 or more hours. 2 scores for qualitative and quantitative morning stiffness were averaged, and total BASDAI score was average of the 5 scores of each symptom, ranging from 0 (none) to 10 (very severe). Higher scores indicate greater disease severity.

Baseline and Week 24

2차 결과 측정

결과 측정
측정값 설명
기간
Change from Baseline in Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein (ASDAS-CRP) at Week 24
기간: Baseline and Week 24

The ASDAS-CRP is a composite of 5 disease activity variables with only partial overlap. The 4 self-reported items included in this index are back pain (VAS), duration of morning stiffness, peripheral pain/swelling, and participant global assessment of disease activity; these are combined with the C-reactive protein (CRP) value. Selected cut-offs for improvement scores are: a change greater than or equal to (>=) 1.1 units for "clinically important improvement" and a change >= 2.0 units for "major improvement.

Baseline and Week 24
Change from Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 24
기간: Baseline and Week 24

DAPSA assessed the joint domain of psoriatic arthritis (PsA) and was derived from the sum of the following components: tender joint count (0-68), swollen joint count (0-66), CRP level (milligram/deciliter [mg/dL], value less than [<] lower limit of quantification [LLOQ] is considered equal to half of the value of LLOQ for numerical calculations), participant assessment of pain (0-10 cm VAS, 0=no pain, 10=worst possible pain), and participant's global assessment of disease activity on arthritis (0 to 10 cm VAS, 0=excellent and 10=poor). A higher score indicates more active disease activity. Negative changes from baseline indicate improvement of PsA disease activity. The assessment does not have a score range with an upper or lower bound.

Baseline and Week 24
Change from Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Week 24
기간: Baseline and Week 24

HAQ-DI score assess functional status of participant. It is 20 question instrument that assess degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0=indicating no difficulty, to 3=indicating inability to perform a task in that area. Total HAQ score is average of the computed categories scores ranging from 0-3 where 0=least difficulty and 3=extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Baseline and Week 24
Percentage of Participants with Investigator's Global Assessment (IGA) 0/1 Response at Week 24 among Participants with >= 3% Body Surface Area (BSA) Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
기간: Week 24

Percentage of participants with IGA 0/1 response at week 24 among the participants with >= 3 percent (%) BSA psoriatic involvement and an IGA score of >= 2 (mild) at baseline will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given timepoint. Overall lesions are graded for induration, erythema, and scaling using 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate) and 4 (severe) scale. The IGA score of psoriasis is based upon the average of induration, erythema and scaling scores. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 24
Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Score for Magnetic Resonance Imaging (MRI) Sacroiliac (SI) Joints at Week 24
기간: Baseline and Week 24

Change from baseline in SPARCC score for MRI SI joints at week 24 among the participants with a positive MRI of the sacroiliac joints at baseline will be reported. SPARCC method focuses on the cartilaginous portion of the SI joint, and scores presence (score of 1) versus absence (score of 0) of bone marrow edema in each SI joint quadrant.

Baseline and Week 24
Percentage of Participants who Achieve a >= 50 % Improvement from Baseline in BASDAI Score at Week 24
기간: Baseline and Week 24

Percentage of participants who achieve a >= 50 % improvement from baseline in BASDAI score at week 24 will be reported.

Baseline and Week 24
Percentage of Participants who Achieve ASDAS Clinically Important Improvement at Week 24
기간: Week 24

Percentage of participants who achieve ASDAS clinically important improvement at week 24 will be reported.

Week 24
Percentage of Participants who Achieve Ankylosing Spondylitis Activity Score (ASAS) 40 Response at Week 24
기간: Week 24

Percentage of participants who achieve ASAS 40 response at Week 24 will be reported. ASAS 40 defined as improvement from baseline of >= 40% and with an absolute improvement from baseline of at least 2 on 0 to 10 cm scale in at least 3 of following 4 domains: Participant's global assessment (0 to 10 cm; 0=very well, 10=very poor), total back pain (0 to 10 cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life), Inflammation (0 to 10 cm; 0=none, 10=very severe); no worsening at all from baseline in remaining domain.

Week 24
Percentage of Participants who Achieve ASDAS Major Improvement at Week 24
기간: Week 24

Percentage of participants who achieve ASDAS major improvement at Week 24 will be reported.

Week 24
Change from Baseline in SPARCC Score for MRI Spine at Week 24
기간: Baseline and Week 24

Change from baseline in SPARCC score for MRI spine at week 24 among the participants with a positive MRI of the spine at baseline will be reported. The SPARCC scoring system for the spine scores the 6 discovertebral units considered by the reader as the most abnormal, and then separately assesses each quadrant of 3 adjacent sagittal slices, with additional points for "depth" and high "intensity" of the lesion.

Baseline and Week 24
Number of Participants with Adverse Events (AEs)
기간: Up to 60 weeks

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 60 weeks
Number of Participants with Serious Adverse Events (SAEs)
기간: Up to 60 weeks

A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

Up to 60 weeks
Number of Participants with Reasonably Related AEs
기간: Up to 60 weeks

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.

Up to 60 weeks
Number of Participants with AEs Leading to Discontinuation of Study Intervention
기간: Up to 60 weeks

Number of participants with AEs leading to discontinuation of study intervention will be reported.

Up to 60 weeks
Number of Participants with Infections
기간: Up to 60 weeks

Number of participants with infections will be reported.

Up to 60 weeks
Number of participants with Injection-Site Reactions
기간: Up to 60 weeks

Number of participants with injection-site reactions will be reported. A study intervention injection-site reaction is any adverse reaction at a subcutaneous study intervention injection-site.

Up to 60 weeks
Number of Participants with Laboratory Abnormalities (Chemistry, Hematology) by Maximum Toxicity (Common Terminology Criteria for Adverse Events [CTCAE 5.0]) Grades
기간: Up to 60 weeks

Number of participants with laboratory abnormalities (chemistry, hematology) by maximum toxicity (CTCAE 5.0) grades will be reported. Grade refers to the severity of the AE as follows: Grade 1- Mild, asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2- Moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental Activities of Daily Living (ADL); Grade 3- Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care ADL; Grade 4- Life-threatening consequences, urgent intervention indicated; Grade 5- Death related to AE.

Up to 60 weeks
Serum Guselkumab Concentration Over Time
기간: Up to 60 weeks

Serum guselkumab concentration over time will be reported.

Up to 60 weeks
Number of Participants with Antibodies to Guselkumab
기간: Up to 60 weeks

Number of participants with antibodies to guselkumab will be reported.

Up to 60 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 8월 30일

기본 완료 (추정된)

2027년 4월 1일

연구 완료 (추정된)

2027년 4월 13일

연구 등록 날짜

최초 제출

2021년 6월 11일

QC 기준을 충족하는 최초 제출

2021년 6월 11일

처음 게시됨 (실제)

2021년 6월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • CR109043
  • 2021-000465-32 (EudraCT 번호)
  • CNTO1959PSA4002 (기타 식별자: Janssen Research & Development, LLC)
  • 2023-504716-15-00 (레지스트리 식별자: EUCT number)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .